$1.04
0.0557[5.66%]
At close: Apr 25
$1.04
0[0.00%]
After Hours: 7:53PM EDT
FibroGen
(NASDAQ:FGEN)FibroGen Stock (NASDAQ:FGEN), Analyst Ratings, Price Targets, Predictions
FibroGen Inc has a consensus price target of $10, established from looking at the 22 latest analyst ratings. The last 3 analyst ratings were released from B of A Securities, Goldman Sachs, and Raymond James on August 8, 2023, June 27, 2023, and June 27, 2023. With an average price target of $1.33 between B of A Securities, Goldman Sachs, and Raymond James, there's an implied 28.21% upside for FibroGen Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
Goldman Sachs
Raymond James
Stifel
William Blair
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for FibroGen
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 08/08/2023 | FGEN | Buy Now | FibroGen | $1.04 | 92.31% | B of A Securities | Jason Gerberry | $4 → $2 | Downgrade | Neutral → Underperform | Get Alert |
| 06/27/2023 | FGEN | Buy Now | FibroGen | $1.04 | 92.31% | Goldman Sachs | Paul Choi | $16 → $2 | Maintains | Sell | Get Alert |
| 06/27/2023 | FGEN | Buy Now | FibroGen | $1.04 | — | Raymond James | Danielle Brill | — | Downgrade | Outperform → Market Perform | Get Alert |
| 06/26/2023 | FGEN | Buy Now | FibroGen | $1.04 | 284.62% | B of A Securities | Jason Gerberry | $29 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 06/26/2023 | FGEN | Buy Now | FibroGen | $1.04 | 957.69% | Stifel | Annabel Samimy | $28 → $11 | Downgrade | Buy → Hold | Get Alert |
| 06/26/2023 | FGEN | Buy Now | FibroGen | $1.04 | — | Raymond James | Danielle Brill | — | Downgrade | Outperform → Market Perform | Get Alert |
| 06/26/2023 | FGEN | Buy Now | FibroGen | $1.04 | — | William Blair | Andy Hsieh | — | Downgrade | Outperform → Market Perform | Get Alert |
| 06/02/2023 | FGEN | Buy Now | FibroGen | $1.04 | — | Stifel | Annabel Samimy | — | Upgrade | Hold → Buy | Get Alert |
| 02/28/2023 | FGEN | Buy Now | FibroGen | $1.04 | 2303.85% | Cowen & Co. | Yaron Werber | $15 → $25 | Maintains | Market Perform | Get Alert |
| 02/23/2023 | FGEN | Buy Now | FibroGen | $1.04 | 1438.46% | Goldman Sachs | Paul Choi | $9 → $16 | Maintains | Sell | Get Alert |
| 02/21/2023 | FGEN | Buy Now | FibroGen | $1.04 | 1438.46% | Goldman Sachs | Paul Choi | $9 → $16 | Maintains | Sell | Get Alert |
| 01/31/2023 | FGEN | Buy Now | FibroGen | $1.04 | — | William Blair | Andy Hsieh | — | Upgrade | Market Perform → Outperform | Get Alert |
| 01/26/2023 | FGEN | Buy Now | FibroGen | $1.04 | 3265.38% | Raymond James | Danielle Brill | → $35 | Upgrade | Market Perform → Outperform | Get Alert |
| 01/05/2023 | FGEN | Buy Now | FibroGen | $1.04 | 2496.15% | B of A Securities | Jason Gerberry | $18 → $27 | Upgrade | Neutral → Buy | Get Alert |
| 11/08/2022 | FGEN | Buy Now | FibroGen | $1.04 | 765.38% | Goldman Sachs | Paul Choi | $8 → $9 | Maintains | Sell | Get Alert |
| 05/24/2022 | FGEN | Buy Now | FibroGen | $1.04 | 669.23% | Goldman Sachs | Paul Choi | $9 → $8 | Maintains | Sell | Get Alert |
| 03/01/2022 | FGEN | Buy Now | FibroGen | $1.04 | 765.38% | Goldman Sachs | Paul Choi | $10 → $9 | Maintains | Sell | Get Alert |
| 09/22/2021 | FGEN | Buy Now | FibroGen | $1.04 | 957.69% | Goldman Sachs | Paul Choi | — | Downgrade | Neutral → Sell | Get Alert |
| 08/20/2021 | FGEN | Buy Now | FibroGen | $1.04 | — | Raymond James | Danielle Brill | — | Upgrade | Underperform → Market Perform | Get Alert |
FAQ
What is the target price for FibroGen (FGEN)?
The latest price target for FibroGen (NASDAQ: FGEN) was reported by B of A Securities on August 8, 2023. The analyst firm set a price target for $2.00 expecting FGEN to rise to within 12 months (a possible 92.31% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for FibroGen (FGEN)?
The latest analyst rating for FibroGen (NASDAQ: FGEN) was provided by B of A Securities, and FibroGen downgraded their underperform rating.
When was the last upgrade for FibroGen (FGEN)?
The last upgrade for FibroGen Inc happened on June 2, 2023 when Stifel raised their price target to N/A. Stifel previously had a hold for FibroGen Inc.
When was the last downgrade for FibroGen (FGEN)?
The last downgrade for FibroGen Inc happened on August 8, 2023 when B of A Securities changed their price target from $4 to $2 for FibroGen Inc.
When is the next analyst rating going to be posted or updated for FibroGen (FGEN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of FibroGen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for FibroGen was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating FibroGen (FGEN) correct?
While ratings are subjective and will change, the latest FibroGen (FGEN) rating was a downgraded with a price target of $4.00 to $2.00. The current price FibroGen (FGEN) is trading at is $1.04, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.